BLAB — Britannia Life Sciences Share Price
Last trade - 00:00- CA$11.36m
- CA$20.90m
- CA$6.40m
- 39
- 77
- 14
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.44 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 9.65 | ||
| Price to Sales | 1.52 | ||
| EV to EBITDA | 8.82 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.84% | ||
| Return on Equity | 24.93% | ||
| Operating Margin | 6.58% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.19 | 0.97 | 0.03 | 7.3 | 6.4 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Britannia Life Sciences Inc. is a Canada-based vertically diversified product development, quality assurance and safety and regulatory compliance company. The Company’s platform offers an integrated suite of services to assist companies along their product development journey. The Company provides product testing, safety assessment and compliance services to the cosmetic, consumer packaged goods and nutraceutical industries in the United Kingdom and globally. It is also engaged in the development and regulatory approval of topical and edible cannabis products, including preparation and support for novel food authorizations. Its services include product formulations, safety assessments, analytical and microbiological testing, global compliance, and consumer evaluations are offered to companies. It serves consumer-packaged goods (CPG), cosmetics, household goods, nutraceutical industries, notable multinationals, retailers, brands, blue-chip and small and medium enterprise clients.
Directors
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 25th, 2002
- Public Since
- December 1st, 2017
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 162,254,339
- Address
- 120 Adelaide Street West; Suite 2400, TORONTO, M5H 1T1
- Web
- http://riselifescience.com/
- Phone
- +1 4169307711
- Auditors
- Zeifman LLP
Upcoming Events for BLAB
Similar to BLAB
Adaptogenics Health
Canadian Securities Exchange
Affinor Growers
Canadian Securities Exchange
Aretto Wellness
Canadian Securities Exchange
AREV Life Sciences Global
Canadian Securities Exchange
Ayurcann Holdings
Canadian Securities Exchange
FAQ
As of Today at 19:04 UTC, shares in Britannia Life Sciences are trading at CA$0.07. This share price information is delayed by 15 minutes.
Shares in Britannia Life Sciences last closed at CA$0.07 and the price had moved by -46.15% over the past 365 days. In terms of relative price strength the Britannia Life Sciences share price has underperformed the Toronto Stock Exchange 300 Composite Index by -48.91% over the past year.
There is no consensus recommendation for this security.
Britannia Life Sciences does not currently pay a dividend.
Britannia Life Sciences does not currently pay a dividend.
Britannia Life Sciences does not currently pay a dividend.
To buy shares in Britannia Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.07, shares in Britannia Life Sciences had a market capitalisation of CA$11.36m.
Here are the trading details for Britannia Life Sciences:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: BLAB
Based on an overall assessment of its quality, value and momentum Britannia Life Sciences is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Britannia Life Sciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -12.66%.
As of the last closing price of CA$0.07, shares in Britannia Life Sciences were trading -19.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Britannia Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Britannia Life Sciences' management team is headed by:
- Scott Secord - CHM
- Robert Lelovic - CFO
- Ashwath Mehra - IND